Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes

But A Comeback Remains Possible

 
• By Andrew McConaghie

Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.

US FDA entrance sign
The FDA is now enforcing the accelerated approval commitments more strictly, including requests for withdrawals. • Source: Sutterstock, JHVEPhoto

More from New Products

More from Scrip